Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

Bausch + Lomb Corp. shares rose the most ever following a report that the eye-care company is considering selling itself to ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

The global ophthalmic eye drop market is poised for steady growth over the next decade. The market, which was valued at USD ...